Ophthalmology · Long Beach, CA
NPI
1518285360
Since 2010
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1945 Palo Verde Ave, Suite #210
Long Beach, CA, 90815
Phone (562) 297-0880
Groups this clinician bills Medicare through
Medicare paid, 2024
$242K
2,918 services
Medicare patients, 2024
711
Average age 70
Drug cost, 2024
$1.8M
9,380 prescriptions
Company payments, 2025
$781
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ravi Menghani was code 92014 (ophthalmological e&m), 944 times for 599 patients. In total Ravi Menghani billed 2,918 services in 29 codes, and Medicare paid $242K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-11-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 92014 Ophthalmological E&M | Office | 944 | 599 | $99.48 | $94K |
| 92250 Angiography | Office | 666 | 530 | $29.63 | $20K |
| 92202 Ophthalmological E&M | Office | 276 | 217 | $12.18 | $3,363 |
| 92134 Computerized Ophthalmic Imaging | Office | 158 | 110 | $32.82 | $5,186 |
| 92012 Ophthalmological E&M | Office | 132 | 99 | $75.58 | $9,977 |
| 92133 Computerized Ophthalmic Imaging | Office | 124 | 113 | $30.05 | $3,726 |
| 92020 Ophthalmological E&M | Office | 121 | 111 | $21.63 | $2,618 |
| 99204 Office E&M - New | Office | 120 | 120 | $114.01 | $14K |
| 92136 Ultrasound - Nonspecific | Office | 83 | 71 | $37.36 | $3,101 |
| 92083 Vision, Hearing, and Speech Services | Office | 83 | 81 | $52.57 | $4,364 |
| 66984 Cataract Surgery | Facility | 77 | 61 | $458.60 | $35K |
| 68761 Eye | Office | 31 | 24 | $170.29 | $5,279 |
| 66821 Cataract Surgery | Office | 24 | 24 | $330.88 | $7,941 |
| 68840 Eye | Office | 18 | 13 | $160.10 | $2,882 |
| 99214 Office E&M - Established | Office | 13 | 12 | $92.55 | $1,203 |
By year: 2022 $216K for 2,334 services; 2023 $243K for 2,597 services; 2024 $242K for 2,918 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ravi Menghani prescribed most often to Medicare patients was Azelastine Hcl, with 1,931 prescriptions and refills. In total Ravi Menghani wrote 9,380 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Azelastine Hcl Generic | 1,931 | 2,576 | 526 | $40K |
| Restasis Cyclosporine | 1,258 | 1,599 | 285 | $945K |
| Latanoprost Generic | 1,030 | 2,160 | 282 | $13K |
| Fluorometholone Generic | 732 | 935 | 563 | $69K |
| Cyclosporine Generic | 650 | 1,000 | 156 | $280K |
| Prednisolone Acetate Generic | 494 | 892 | 289 | $29K |
| Brimonidine Tartrate Generic | 438 | 762 | 102 | $7,232 |
| Ketorolac Tromethamine Generic | 382 | 673 | 216 | $8,670 |
| Ofloxacin Generic | 374 | 663 | 233 | $9,000 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 368 | 676 | 93 | $6,814 |
| Timolol Maleate Generic | 230 | 500 | 71 | $4,458 |
| Cequa Cyclosporine | 230 | 233 | 47 | $124K |
| Cromolyn Sodium Generic | 170 | 260 | 62 | $2,332 |
| Erythromycin Erythromycin Base | 141 | 141 | 78 | $1,361 |
| Vyzulta Latanoprostene Bunod | 109 | 186 | 24 | $53K |
Brand drugs: 4,108 claims; generic drugs: 5,272 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ravi Menghani $781 ($781 in general payments such as food, travel and fees) from 9 companies. The largest payer was Sun Pharmaceutical Industries Inc. with $237.
| Company | Payments | Amount |
|---|---|---|
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 12 | $237 |
| Alcon Vision LLC ALC | 7 | $160 |
| Tarsus Pharmaceuticals, Inc. TARS | 3 | $98.87 |
| Harrow Eye, LLC | 3 | $85.78 |
| Amgen Inc. AMGN | 3 | $63.77 |
| Dompe US, Inc. | 2 | $45.62 |
| Bausch & Lomb Americas Inc. BLCO | 2 | $41.65 |
| Mallinckrodt Hospital Products Inc. | 1 | $24.57 |
| Thea Pharma Inc. | 1 | $23.88 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.